Back to Search
Start Over
Integrating multi-level interactive network and in vivo/vitro studies to explore the protective mechanism of Ampelopsis grossedentata in hyperuricemia.
- Source :
-
Fitoterapia . Jan2024, Vol. 172, pN.PAG-N.PAG. 1p. - Publication Year :
- 2024
-
Abstract
- The strategies or drugs for preventing and treating Hyperuricemia (HUA) are still lacking. As a traditional Chinese medicine (TCM) with a profound history, Ampelopsis grossedentata has been shown to play diverse biological roles. The purpose of the present study was to evaluate hypouricemic effect of A. grossedentata , and investigate its involved material basis and mechanism. A HUA mice model was established to evaluate the therapeutic effects of A. grossedentata. And then some extracts from A. grossedentata were prepared, isolated and analyzed. Furthermore, network pharmacology, based on the above results, was used to discover potential active ingredients and therapeutic targets, and they were further verified and explored by molecular docking and in vitro experiments. In vivo experiments showed that A. grossedentata exerted hypouricemic effect on mice of HUA. The core active ingredients (quercetin, myricetin and dihydromyricetin etc.) and core targets (PTGS2, XOD and ABCG2 etc.) for A. grossedentata to treat HUA were predicted by network pharmacology. And molecular docking showed that the spontaneous binding activities of above components and targets were marvelous. In vitro experiments further demonstrated that A. grossedentata exerted hypouricemic effect by decreasing the levels of UA, XOD, antioxidant factors, inflammatory factors, GLUT9 and URAT1 in HK-2 cells of HUA. Taken together, this study integrates multi-level interaction network with in vivo / vitro experiments to systematically reveal the material basis and mechanism of A. grossedentata in treating HUA, which provides a scientific basis for further study of A. grossedentata and HUA. [Display omitted] • Hypouricemic effect of A. grossedentata was confirmed in vivo experiment. • Ten components of A. grossedentata were obtained, and trifolirhizin was obtained from A. grossedentata at the first. • The potential material basis and mechanism of A. grossedentata in the treatment of hyperuricemia such as multiple components, multiple targets and multiple pathways were systematically explored by the multi-level interaction network. • The potential material basis and mechanism of A. grossedentata in the treatment of hyperuricemia such as multiple components and multiple targets were further verified and investigated in vitro experiment. [ABSTRACT FROM AUTHOR]
- Subjects :
- *HYPERURICEMIA
*IN vitro studies
*MEDICINAL plants
*HERBAL medicine
*GOUT suppressants
*IN vivo studies
*FLAVONOIDS
*ANIMAL experimentation
*ANTIOXIDANTS
*GLYCOSIDES
*QUERCETIN
*XANTHINE
*COMPUTER-assisted molecular modeling
*PLANT extracts
*PHARMACEUTICAL chemistry
*URIC acid
*CHINESE medicine
*MICE
*PHARMACODYNAMICS
*THERAPEUTICS
Subjects
Details
- Language :
- English
- ISSN :
- 0367326X
- Volume :
- 172
- Database :
- Academic Search Index
- Journal :
- Fitoterapia
- Publication Type :
- Academic Journal
- Accession number :
- 174666422
- Full Text :
- https://doi.org/10.1016/j.fitote.2023.105718